Bristol Myers Squibb Announces ZENBEXUSTM (iberdomide) in Combin

Bristol Myers Squibb reported positive results from a Phase 3 trial for Zenbexus, a treatment for multiple myeloma. The drug is already FDA-approved for another blood cancer. The trial success could expand Zenbexus's market potential.

Bristol Myers Squibb (BMY) reported positive Phase 3 trial results for its multiple myeloma treatment, showing a 51% reduction in disease progression risk. The company offers a 4.08% dividend yield with a 41% payout ratio and a GF Score of 72/100. Institutional interest is mixed, with some gurus adding and others trimming positions.

Bristol Myers Squibb (BMY) reported that its Phase 3 EXCALIBER-RRMM study met its primary endpoint, showing a 51% reduction in disease progression or death risk for relapsed or refractory multiple myeloma patients treated with ZENBEXUS-based therapy. Median progression-free survival was 42 months compared to 20 months with the comparator regimen, with no new safety concerns noted.

Bristol Myers Squibb (BMY) received expanded FDA approval for CAMZYOS, now including pediatric patients. The stock rose 1.33% on the news but has declined 5.20% over 7 days and 10.82% over 30 days. Analysts' price targets average $66, with the company trading at $59.59. Revenue from growth portfolio reached $7.6b in Q2 2026, nearly 60% of total sales.

A phase 3 trial showed that combining iberdomide with daratumumab and dexamethasone improved MRD-negative complete response rates in relapsed/refractory multiple myeloma patients compared to the standard regimen. The iberdomide group had a 41% response rate vs 21% in the control group, but higher adverse events. The study was published in The Lancet Oncology and supported by Bristol Myers Squibb, with some authors having ties to the company.

Global healthcare companies, including Pfizer, Eli Lilly, and AstraZeneca, are investing billions in US manufacturing and research. Pfizer plans $70B, Eli Lilly $27B, and AstraZeneca $50B. Investments aim to mitigate supply-chain risks and tariff impacts, with some companies reporting minimal 2025 tariff effects.